» Articles » PMID: 23762597

The Effect of Pioglitazone on Antioxidant Levels and Renal Histopathology in Streptozotocin-induced Diabetic Rats

Overview
Journal ISRN Endocrinol
Specialty Endocrinology
Date 2013 Jun 14
PMID 23762597
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective. Diabetic nephropathy is the most commonly seen cause of chronic renal failure, and oxidative stress is important in etiology. In the present study, favorable effects (if any) of the treatment with a thiazolidinedione group drug, pioglitazone, on antioxidant enzyme levels in the renal tissue, renal histopathology, and inflammatory cytokine levels have been investigated. Method. Forty male Wistar rats were divided into 4 groups as the control, diabetic control, and 10 and 30 mg pioglitazone-administered diabetic groups. After 4 weeks, antioxidant enzyme levels in renal tissues and inflammatory markers were investigated. Results. Blood glucose levels did not differ between the diabetic control and drug-administered groups. In pioglitazone-administered rats, histopathological findings such as tubular dilation, necrotic tubular epithelium, glomerular focal necrosis, and vascular consolidation were observed at a lesser extent than the diabetic control group. Any difference was not detected between the diabetic groups with respect to the levels of malondialdehyde, superoxide dismutase, catalase, glutathione, nitric oxide, interleukin-6, and tumor necrosis factor-alpha. Conclusion. Pioglitazone regressed development of histopathological lesions such as glomerular focal necrosis, tubular epithelial necrosis, tubular dilation, and vascular wall consolidation. However, any favorable effect on antioxidant enzyme levels in renal tissues and inflammation markers was not detected.

Citing Articles

Mesoporous silica and alumina nanoparticles to improve drug delivery of pioglitazone on diabetic type 1 nephropathy in rats.

Varshosaz J, Ahmadipour S, Dezhangfard A Res Pharm Sci. 2024; 19(4):459-474.

PMID: 39399726 PMC: 11468168. DOI: 10.4103/RPS.RPS_65_23.


Evaluation of the protective effect of Curcuma longa and PPARγ agonist, pioglitazone on paraquat-induced lung injury in rats.

Eshaghi Ghalibaf M, Taghavi Zadeh Yazdi M, Mansourian M, Mohammadian Roshan N, Boskabady M Immun Inflamm Dis. 2024; 12(8):e70001.

PMID: 39172009 PMC: 11340013. DOI: 10.1002/iid3.70001.


Pioglitazone enhances brain mitochondrial biogenesis and phase II detoxification capacity in neonatal rats with 6-OHDA-induced unilateral striatal lesions.

Vazquez-Gonzalez D, Corona J Front Neurosci. 2023; 17:1186520.

PMID: 37575308 PMC: 10416244. DOI: 10.3389/fnins.2023.1186520.


Prophylactic and Ameliorative Effects of PPAR-γ Agonist Pioglitazone in Improving Oxidative Stress, Germ Cell Apoptosis and Inflammation in Gentamycin-Induced Testicular Damage in Adult Male Albino Rats.

El-Sayed K, Ali D, Maher S, Ghareeb D, Selim S, Albogami S Antioxidants (Basel). 2022; 11(2).

PMID: 35204074 PMC: 8868260. DOI: 10.3390/antiox11020191.


Pioglitazone abrogates testicular damage induced by testicular torsion/detorsion in rats.

Mahmoud N, Kabil S Iran J Basic Med Sci. 2019; 22(8):884-892.

PMID: 31579444 PMC: 6760474. DOI: 10.22038/ijbms.2019.33199.7929.


References
1.
Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

2.
Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

3.
Desfaits A, Serri O, Renier G . Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Diabetes Care. 1998; 21(4):487-93. DOI: 10.2337/diacare.21.4.487. View

4.
Adler A, Stevens R, Manley S, Bilous R, Cull C, Holman R . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2002; 63(1):225-32. DOI: 10.1046/j.1523-1755.2003.00712.x. View

5.
Vantyghem M, Balduyck M, Zerimech F, Martin A, Douillard C, Bans S . Oxidative markers in diabetic ketoacidosis. J Endocrinol Invest. 2001; 23(11):732-6. DOI: 10.1007/BF03345062. View